Answers are grounded in this paper and cite their sources.
Methylphenidate is increasingly used off-label by healthy adults seeking cognitive enhancement despite limited evidence supporting its efficacy outside attention-deficit/hyperactivity disorder (ADHD). Most studies in healthy populations employ acute, single-dose designs and report inconsistent findings across cognitive domains. This study aimed to evaluate the effects of prescription stimulants on cognition in healthy adults and to determine whether sustained administration of extended-release methylphenidate confers neurocognitive benefits beyond placebo. A two-part study was conducted. First, a systematic review examined placebo-controlled studies evaluating prescription stimulants and objective neurocognitive performance in healthy adults. Second, a randomised, double-blind, placebo-controlled crossover trial was performed in 28 healthy, drug-naïve adults (25 females, 3 males; mean age 30.2 ± 10.8 years). Participants received extended-release methylphenidate (20 mg/day) and placebo for 14 days each, separated by a 48-hour washout period. Neurocognitive performance was assessed using the CNS Vital Signs ® battery at baseline and after each intervention period across six cognitive domains. The systematic review identified 10 eligible studies and demonstrated that prescription stimulants produce small, domain-specific improvements, most consistently in sustained attention, inhibitory control, and episodic memory. Meta-analytic evidence indicated only modest overall effects for methylphenidate (standardized mean difference approximately 0.21). In the clinical trial, executive function, cognitive flexibility, and reaction time improved significantly from baseline following both methylphenidate and placebo administration (all p < 0.05). However, no significant differences were observed between methylphenidate and placebo for any neurocognitive outcome (all p > 0.05), with negligible between-condition effect sizes (overall Cohen’s d = 0.17). Current evidence suggests that prescription stimulants produce only modest and domain-specific cognitive effects in healthy adults. In this randomised crossover trial, short-term administration of extended-release methylphenidate did not improve neurocognitive performance beyond placebo. The observed improvements appear more consistent with practice, expectancy, and task-familiarity effects than with sustained pharmacological enhancement. These findings challenge assumptions regarding the effectiveness of off-label stimulant use for cognitive enhancement in healthy individuals. Pan African Clinical Trials Registry (PACTR202011697726048 registered 11 November 2020) and ClinicalTrials.gov (NCT07742631 registered 28 July 2026).
No takes yet. Share an insight, caveat, or question.
Constantinou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: